LONDON, Aug. 26 /PRNewswire/ -- IDIS, the world leader in the
development and implementation of pre-launch Named Patient Programs (NPPs),
announces the opening of a new regional office in Iselin, New Jersey, USA.
This office places IDIS in a stronger position to support US based
pharmaceutical companies in the implementation of programs to support early
access of their medicines.
NPPs provide drug developers across the world with a legal and ethical
way to make medicines available where appropriate, in response to requests
made by physicians, when those medicines are not yet approved in their
country or in late-stage clinical trials. The programs that IDIS
establishes in partnership with pharmaceutical and biotechnology companies
must adhere to the strict regulatory guidelines of the country from which
the request originates to allow patients, who have a genuine unmet medical
need, with access to potentially life-saving medicines.
The Iselin office will be headed by John Lagus, Vice President of
Business & Corporate Development, IDIS, who is leading the expansion of
IDIS in the US.
John Lagus said: "This expansion is critical for building our presence
in the US for all our global partners, as well as providing proximity to
the pharmaceutical and biotechnology companies based in the US. This new
office demonstrates IDIS' commitment to our clients, who requested we
establish a US presence, and helps the business to further deliver global
market access for the pharmaceutical and biotechnology industry through
named patient programs, as well as comparator drug sourcing."
In support of companies sponsoring comparative effectiveness clinical
trials, IDIS has built expertise in the strategy for and the procurement of
comparator drugs. IDIS has a dedicated procurement team that is focused
exclusively on identifying reputable sources for comparator drugs from
around the world, achieved as a result of extensive and long-running
relationships with drug manufacturers.
About IDIS ...
Founded in the UK in 1987, IDIS expanded into Europe six years later,
with US pharmaceutical and biotechnology strategic partners established in
the last 10 years. IDIS is the world leader in the development and
implementation of NPPs.
IDIS is headquartered near central London.
Visit the IDIS website at http://www.idispharma.com.
Contact: Lynn Blenkhorn of Feinstein Kean Healthcare, +1-508-851-0930
SOURCE IDIS
 back to top
Related links:
http://www.idispharma.com
CONTACT:
Lynn Blenkhorn of Feinstein Kean Healthcare,
+1-508-851-0930
|
